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Life expectancy in the United States fares poorly in international comparisons, primarily because of
high mortality rates above age 50. Its low ranking is often blamed on a poor performance by the health
care system rather than on behavioral or social factors. This paper presents evidence on the relative
performance of the US health care system using death avoidance as the sole criterion. We find that,
by standards of OECD countries, the US does well in terms of screening for cancer, survival rates
from cancer, survival rates after heart attacks and strokes, and medication of individuals with high
levels of blood pressure or cholesterol. We consider in greater depth mortality from prostate cancer
and breast cancer, diseases for which effective methods of identification and treatment have been developed
and where behavioral factors do not play a dominant role. We show that the US has had significantly
faster declines in mortality from these two diseases than comparison countries. We conclude that the
low longevity ranking of the United States is not likely to be a result of a poorly functioning health
care system.
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  The United States falls well behind the world’s leaders in life expectancy at birth. Some 
of the discrepancy is attributable to relatively high infant mortality and some to high mortality 
from violence among young adults. But the bulk of the discrepancy is attributable to mortality 
above age 50, an age to which 94% of newborns in the United States will survive according to 
the 2006 US life table. Life expectancy at age 50 in the United States ranks 29
th highest in the 
world in 2006 according to the World Health Organization (WHO 2009). It falls 3.3 years behind 
the leader, Japan, and more than 1.5 years behind Australia, Canada, France, Italy, Iceland, 
Spain, and Switzerland. About 4 million Americans reach age 50 each year, so that an average 
loss of 1.5 years of life years per person means that some 6 million years of potential life are 
being lost annually. At the conventional value of $100,000 per additional year of life (Cutler 
2004), the relative loss of life in the US above age 50 is valued at roughly $600 billion annually. 
Using Japan as a standard, the loss is $1.3 trillion. 
  Analysts often juxtapose the poor ranking of the United States in life expectancy and the 
very high percentage of its gross national product that is spent on health care. In 2007, the United 
States spent 16% of its GDP on health care, by far the highest fraction of any country 
(Congressional Budget Office 2007). The conclusion that is often drawn from this combination is 
that the United States’ health care system is extremely inefficient (e.g., Anderson and Frogner 
2008). 
  But measures of population health such as life expectancy do not depend only on what 
transpires within the health care system – the array of hospitals, doctors and other health care 
professionals, the techniques they employ, and the institutions that govern access to and 
utilization of them. Such measures also depend upon a variety of personal behaviors that affect 
an individual’s health such as diet, exercise, smoking, and compliance with medical protocols. 
The health care system could be performing exceptionally well in identifying and administering 
treatment for various diseases, but a country could still have poor measured health if personal 
health care practices were unusually deleterious. This is not a remote possibility in the United 
States, which had the highest level of cigarette consumption per capita in the developed world 
over a 50-year period ending in the mid-80’s (Forey et al. 2002). Smoking in early life has left an 
imprint on mortality patterns that remains visible as cohorts age (Preston and Wang 2006; 
Haldorsen and Grimsrud 1999). One recent study estimated that, if deaths attributable to 
smoking were eliminated, the ranking of US men in life expectancy at age 50 among 20 OECD   2
countries would improve from 14
th to 9
th, while US women would move from 18
th to 7
th (Preston, 
Glei, and Wilmoth 2009). Recent trends in obesity are also more adverse in the United States 
than in other developed countries (OECD 2008; Cutler, Glaeser, and Shapiro 2003).  
  This paper begins with a review of previous international studies of the comparative 
performance of health care systems. The review is focused on the major diseases of adulthood, 
cancer and cardiovascular disease, in the belief that disease-level analyses are more likely to 
reveal the forces at work than more highly aggregated studies (Garber 2003). In 2005, cancer and 
major cardiovascular diseases were responsible for 61.0% of deaths in the US at ages 45+ (US 
National Center for Health Statistics 2008). Because our concern is with mortality per se, the 
criterion we employ is effectiveness at preventing death, rather than cost-effectiveness or 
efficiency of resource deployment. These latter criteria have been used in several other recent 
comparative studies with a financial focus (Garber and Skinner 2008; McKinsey Global Institute 
2008). 
  Health systems can prevent death from a particular disease either by preventing a disease 
from developing or by effectively treating it once it has developed. A key element in effective 
treatment is accurate diagnosis. Unfortunately, almost no internationally comparable data exist 
on the actual incidence of various diseases, which is the appropriate measure of the success of 
prevention. While cancer appears to be an exception because “incidence” data are published for 
various cancer registry sites (e.g., at the website of the International Agency for Research on 
Cancer), the data refer not to the origin of a disease but to its detection, a process that combines 
actual patterns of incidence with the mechanics of identification. And even if pure measures of it 
were available, actual disease incidence reflects not only features of a health system but also 
many other factors of behavioral, social, and genetic origin.  
  Disease prevalence – the proportion of the population that has been diagnosed with a 
disease – is even more difficult to interpret. The United States has a higher prevalence than 
Europe of the major adult diseases, including cancer, heart disease, and diabetes (Thorpe et al. 
2007a; Avendano et al. 2009). But higher prevalence could reflect higher incidence, better 
detection, or longer survival resulting from more successful treatment. Because of these 
limitations of data and interpretation, our review will focus primarily on disease identification 
and treatment, elements that are customarily considered to be the provenance of health care 
systems.     3
  A valuable but not unimpeachable indicator of the effectiveness of treatment is the 
comparative survival rate of individuals once a disease has been detected. Relatively high 
survival rates imply either that the disease has been detected unusually early or that treatment is 
unusually successful. Early detection is valuable to the extent that it permits better therapy. 
However, if early detection did not alter the clinical course of a disease but only increased the 
expected length of time from detection to death (so-called “lead time bias”), then it would not be 
associated with reductions in mortality at the population level despite raising 5-year survival 
rates (e.g., Gatta et al. 2000).   
  Because they are not subject to this potential bias, we pay special attention to mortality 
rates. In particular, in the second half of the paper we investigate comparative mortality trends 
for prostate cancer and breast cancer. We document that  
•  effective methods of screening for these diseases have been developed relatively 
recently; 
•  these diagnostic methods have been deployed earlier and more widely in the US 
than in most comparison countries; 
•  effective methods are being used to treat these diseases; and 
•  the US has had a significantly faster decline in mortality from these diseases than  
            comparison countries.  
 
 International Studies of Cancer 
  The United States does well in international comparisons of the frequency of cancer 
screening. The OECD (2006, 2007) provides 2000-05 data on the percentage of women aged 20-
69 in 15 countries who had been screened for cervical cancer during the preceding three years. 
The US has the highest percentage of women who have been screened in both tabulations.
1 We 
present evidence below that the US also has exceptionally high screening rates for prostate 
cancer and breast cancer. Quinn (2003) reports colorectal screening rates in the US that are 
“quite high” in comparison to Europe but does not provide comparative data. Gatta et al. (2000: 
899) also suggest that access to and use of sigmoidoscopy, colonoscopy, and fecal occult blood 
tests are more common in the US than in Europe. This difference is supported by the finding that 
                                                 
1 Ages vary somewhat but the variation is thought to be a “minor threat” to the validity of comparisons (OECD 
2006:69). The 15 countries include 6 for whom the recall period is greater than 3 years, the period used in the US.   4
colorectal cancer patients in the US have less advanced disease at diagnosis than patients in 
Europe (Ciccolallo et al. 2005). 
  A higher rate of screening for cancer would produce a higher prevalence of ever-
diagnosed cancer in the population, ceteris paribus. The elevated prevalence would occur simply 
because a higher fraction of the population would know about their disease. An additional boost 
to prevalence would be provided if early detection resulted in reduced mortality. Thus, in view of 
the higher frequency of screening in the US, we would expect its reported prevalence of 
diagnosed cancer to be higher than in Europe.  
  That expectation is confirmed by data from the Health and Retirement Survey and its 
English and European counterparts. Thorpe et al. (2007a) find that 12.2% of Americans over age 
50 report having been diagnosed by physicians with cancer, compared to only 5.4% in a 
composite of 10 European countries. Avendano et al. (2009) report similar figures for the age 
range 50-74, with England intermediate between the US and Europe but closer to Europe. Some 
fraction of these very large differences in prevalence could, of course, be attributable to real 
differences in disease incidence or to reporting differences, which are discussed briefly below. 
  Thanks to a large number of cancer registries that record new cancer diagnoses and 
follow individuals forward from the point of diagnosis, 5-year survival rates for people initially 
diagnosed with cancer are widely available to provide evidence about the success of detection 
and treatment. Because of their relative comparability and pertinence to a major disease process, 
these data are among the best indicators of comparative health system performance. In this 
summary, we use 5-year relative survival rates, which compare the survival of those diagnosed 
with cancer to that of an average person of the same age and sex as the person diagnosed. 
  International comparisons of cancer survival rates show a distinct advantage for the US. 
Using cancer registry data, researchers from the Eurocare Working Group compare 5-year 
survival rates for cancers of 12 sites that were diagnosed between 1985 and 1989 (Gatta et al. 
2000). The aggregate of 41 European registries, which were drawn from 17 countries, had lower 
survival rates than the US from all cancer sites except the stomach, where differences were small 
and attributed to differences between the distributions of sites within the stomach. The US data 
were drawn from the National Cancer Institute’s Surveillance, Epidemiology and End Results 
(SEER) database, a population-based cancer registry covering approximately 14% of the US 
population. For the major sites of lung, breast, prostate, colon, and rectum cancers, US survival   5
rates were the highest of any of the 18 countries investigated. Cancers first diagnosed on the 
death certificate (5% in Europe and 1% in the US) were excluded from analysis; if they had been 
included, the US survival advantage would have increased. The authors discount the possibility 
that the US advantage was attributable to statistical or registration artifacts.  
  An updated analysis reached similar conclusions. Based upon period survival data for 
2000-02 from 47 European cancer registries, 5-year survival rates were found to be higher in the 
US than in a European composite for cancer at all major sites (Verdecchia et al. 2007). Table 1 
presents the comparative data for all sites for which the US 95% confidence interval was <0.025. 
For men (all sites combined), 47.3% of Europeans survived 5 years, compared to 66.3% of 
Americans. For women, the contrast was 55.8% vs. 62.9%. The male survival difference was 
much greater than the female primarily because of the very large difference in survival rates 
from prostate cancer.   
  Thus, the US appears to screen more vigorously for cancer than Europe and people in the 
US who are diagnosed with cancer have higher 5-year survival probabilities. Scattered data for 
cancer of various sites indicate that tumors are typically detected at an earlier stage in the US 
(Gatta et al. 2000; Sant et al. 2004; Ciccolallo et al. 2005). Of course, all of these phenomena 
could be the exclusive product of lead-time bias if early detection afforded no benefit for the 
clinical course of the disease. Below, we present evidence that innovations in diagnosis and 
treatment of prostate and breast cancer were associated with faster declines in mortality in the 
US than in OECD countries. Such a pattern would not be observed if lead time bias were the 
only factor at work, i.e., if early detection conferred no advantage.  
 
International Studies of Cardiovascular Disease 
  In contrast to cancer, nations do not have registries for heart disease and stroke. So  
information about the comparative performance of medical systems in respect to cardiovascular 
disease is not as systematic and orderly as it is for cancer. One useful source of comparative data 
is the Health and Retirement Survey (HRS) and its European counterparts, the Survey of Health, 
Aging, and Retirement in Europe (SHARE). Thorpe et al. (2007a) compare the US to a 
composite of 10 European countries on the frequency with which people with a particular 
diagnosis report using medication. Of people aged 50+ diagnosed with heart disease, 60.7% of 
Americans and 54.5% of Europeans report being on medication. The proportions using   6
medication after a stroke are comparable at 45.1% and 44.6%. Of those reporting high 
cholesterol levels, 88.1% of Americans report being medicated vs. 62.4% of Europeans.
2 
Crimmins, Garcia, and Kim (2009) show that a much higher fraction of Americans are using 
lipid-lowering drugs at a particular age than in Japan, the Netherlands, or Italy, even though 
proportions with elevated cholesterol in these countries are similar to or higher than that in the 
US.  
  Among those reporting high blood pressure in HRS and SHARE, the proportions 
reporting taking medication for the condition are similar in the US (88.0%) and Europe (88.9%) 
(Thorpe et al. 2007a). However, when actual measures of blood pressure are used rather than self 
reports, the position of the US improves. Wolf-Maier et al. (2004) employ regional or national 
samples in the US, Canada, and five European countries. Hypertension is defined as the 
population of persons who have systolic blood pressure of 160+ or diastolic blood pressure of 
95+ or who are using antihypertensive medication. Of persons aged 35-64 with hypertension, 
77.9% were being treated in the US, compared to a range of 41.0% - 62.4% in the other six 
countries. Among those with hypertension, 65.5% were being successfully treated in the US (i.e., 
their levels were reduced below the hypertension-defining threshold), compared to 24.8% to 
49.1% in the other countries.       
  Survival data for cardiovascular disease start not from the point of diagnosis but from an 
acute event of heart attack or stroke. An OECD study, following up on a study by the TECH 
network, computed one-year case fatality rates for people hospitalized for acute myocardial 
infarction (AMI) in Australia, Canada, Denmark, Finland, Sweden, Great Britain, and the US. 
The samples were sometimes regionally rather than nationally representative. Among the seven 
countries in 1996, the US had the third lowest case-fatality rate for males aged 40-64 and the 
second-lowest rate for men aged 85-89. For women at these ages, the US ranked fourth and first 
(Moise 2003).  Part of the explanation of the better performance of the US may be related to its 
unusually aggressive treatment regime. Of the seven countries, the US had the highest proportion 
of male and female patients in both age intervals undergoing revascularization operations 
(percutaneous transluminal coronary angioplasty or coronary artery bypass graft) (Ibid.; see also  
                                                 
2 The US figure for cholesterol is drawn from the Medicare Expenditure Panel Survey because HRS did not gather 
this information.   7
Technological Change in Health Care (TECH) Research Network 2001).
3  
  One study has explicitly linked more aggressive surgical treatment in the US to better 
outcomes. It compared Canadians and Americans who had just experienced an AMI and who 
enrolled in a drug trial (Kaul et al. 2004). Data are not nationally representative but rather reflect 
the patient-base of hospitals participating in the trial. Americans had a small but statistically 
significant advantage in 5-year survival. Controlling many baseline characteristics, the hazard 
rate was 17% higher in Canada. When revascularization was added to the model, it was 
associated with a 28% reduction in the hazard rate and its addition reduced the international 
difference to an insignificant 7%. The authors conclude that “…our findings are strongly 
suggestive of a survival advantage for the US cohort based on more aggressive 
revascularization” (Ibid., p. 1758).  
  OECD (2003) has conducted a large international study of ischaemic stroke, which 
accounts for roughly 88% of stroke cases except in Japan, where it represents about 70%. They 
calculate in-hospital 7-day and 30-day survival rates for patients newly admitted with ischaemic 
stroke. For both men and women aged 65-74, the US ranking on 7-day survival rates was 3
rd out 
of 9; at ages 75+, it was 2
nd out of 9 for both sexes. For 30-day hospital survival rates at ages 65-
74, the US was 2
nd for women and tied for 2
nd with two others among men. At ages 75+, the US 
30-day survival rate was 1
st for men and 2
nd for women. Counting all deaths and not simply 
deaths in the hospital, and limiting comparison to six regions including two in Canada, the US 
survival rate ranked 1
st for men aged 65-74 and 75+ and second for women in these ages. 
However, the US one-year survival rate among this set of populations was considerably poorer, 
ranking 5
th of 6 for men aged 65-74 and 4
th of 6 for men aged 75+. For women at these two ages, 
the rankings were 4
th and 3
rd. Consistently in these rankings, the US position was better at 75+ 
than at 65-74.  
 Carotid  endarterectomy  (surgical removal of plaque from inside the carotid artery) is used 
to prevent stroke or the recurrence of stroke. Such surgery is much more common in the US than 
in any of 11 comparison OECD countries (OECD 2003). We are unaware of any studies linking 
this surgery to international patterns of stroke mortality, but a randomized clinical trial reports a 
large survival advantage for persons undergoing the procedure (Halliday et al. 2004). 
 
                                                 
3 Data on treatments at ages 85-89 were not available for Spain or the United Kingdom.   8
Contrary Evidence? “Mortality Amenable to Medical Care” 
  The Commonwealth Fund (2008) has recently issued a “scorecard” on US health system 
performance that consists of 37 indicators. The highly publicized report concludes that the 
United States lags far behind its peers in measures of health system performance. Most of the 
indicators use benchmarks that are established by consultation with experts or by values in best-
performing states. But several are based on international comparisons. The international index 
that receives the most attention is “Mortality amenable to medical care”, on which the US 
currently ranks last among 19 countries. This index is developed and applied in Nolte and 
McKee (2008), where amenable deaths are described as “deaths from certain causes that should 
not occur in the presence of timely and effective health care” (p. 59). Only deaths below age 75 
are included, which constitute 43.2% of deaths in the US in 2005 (US National Center for Health 
Statistics 2008).  For some causes of death, an earlier age cutoff is used.  
  The distribution of major causes of death included among the “amenable causes” is 
provided for the US, the United Kingdom, and France (Nolte and McKee 2008). A majority of 
amenable deaths in all three countries is attributed to ischemic heart disease and other circulatory 
diseases, even though only half of ischemic heart disease deaths are included because some are 
believed not to be amenable to health care. That rule of thumb is clearly a poor substitute for an 
effort to attribute international variation in mortality from ischemic heart disease to its various 
components, including health care systems and behavioral and social factors.
4 The authors note 
that a similar rule of thumb could have been introduced for cerebrovascular diseases, which 
constitute at least a quarter of the “amenable” deaths in the US and UK. But it would have been 
no more satisfactory for that cause of death.      
In view of the studies that show that the US does relatively well in treating cardiovascular 
disease, it seems inaccurate to attribute its high death rates from these causes to a poorly 
performing medical system. And these diseases contribute a majority of their set of amenable 
deaths, rendering the totality of amenable causes problematic. A related objection could be raised 
to the inclusion of diabetes deaths in the set. On the other hand, prostate cancer is excluded from 
the list of amenable causes despite the fact that the 5-year survival rate from prostate cancer in 
the US is above 99% and the disease can be readily identified (see below). 
                                                 
4 The strategy adopted by Nolte and McKee is no different from saying that genetic factors play some role in 
cardiovascular mortality and, as a consequence, attributing half of international variation in cardiovascular mortality 
to genetic factors.   9
  According to Nolte and McKee (2008), males in the United States had a faster fall in 
mortality from non-amenable causes of death (an 8% decline) than from amenable ones (4%) 
between the latest two readings, 1997/8 and 2002/3. This anomaly suggests either flaws in the 
index or the unimportance of medical care relative to other factors that are operating.   
  Causes of death whose inclusion in Nolte and McKee’s list of amenable causes at older 
ages is more defensible are influenza and pneumonia. Mortality from both causes is heavily 
influenced by smoking (Centers for Disease Control and Prevention 2002), so the international 
distribution of mortality is a product of factors beyond the health care system. On the other hand, 
influenza is partially immunizable and death from pneumonia can often be avoided through 
administration of vaccines or antibiotics or improvements in hospital sanitation.  
  The US ranks 9
th of 23 OECD countries in the proportion of the population above age 65 
offered an annual influenza vaccination (OECD 2007). Figure 1 demonstrates that the 2000-04 
age-standardized death rate from influenza at ages 50+ in the United States is among the lowest 
of the 16 countries investigated. The US fares less well in mortality from pneumonia, ranking 6
th 
worst among the 16 countries investigated (Figure 2). However, the ranking is somewhat 
deceiving because its death rate is closer to all but one of the better-ranked countries than to the 
five countries with higher rates. The US death rate from pneumonia at ages 50+ is actually below 
the weighted or unweighted mean for the other 15 countries. 
 
Disease Prevention 
  Medical procedures and survival rates are indicators of what happens to individuals  
whose health problems come to the attention of the health care system. But a health care system 
can also help prevent serious health problems from occurring in the first place. Of course, early 
identification of a disease is also preventative medicine in the sense that it may prevent death. 
But access to preventive medicine would appear to be an especially problematic area in the 
United States because 47 million people lack any form of health insurance (DeNavas-Walt, 
Proctor, and Smith 2007).
5 Such people are less likely to see a doctor and thus to receive routine 
testing that might detect the early stages of a disease and prevent its clinical manifestations 
(Institute of Medicine 2001). They are also less likely to receive advice about health maintenance  
                                                 
5 It has been claimed that this number includes 10 million people who are in fact covered by Medicaid insurance but 
who fail to report it (Ohsfeldt and Schneider 2006).     10
and disease prevention (Ibid.).  
  An additional factor that may inhibit disease prevention in the US is the shortage of 
primary care physicians. The US scores in the bottom group of 6 out of 18 OECD countries on a 
scale of the adequacy of primary care (Macinko, Starfield, and Shi 2003). The scale is built from 
items relating to policy, finances, and personnel. In turn, the adequacy of primary care may be 
related to disease prevention (Ibid.)  
The best indication of the success of prevention is disease incidence. But international 
data on disease incidence are nil. As noted earlier, disease prevalence is higher in the US than in 
a European composite for cancer, heart disease, stroke, chronic lung disease, and diabetes 
(Thorpe et al. 2007a). However, such a difference could result from higher incidence in the US, 
better detection, or longer survival after detection. It could also result from reporting differences, 
e.g., a greater inclination to report disease in the US. But a careful study by Banks et al. (2006) 
using biomarkers suggests that morbidity differences between England and the US at ages 55 to 
64 are real and not a result of differences in reportage. One related study found that, faced with 
the same set of health-related vignettes, Americans were less likely to report themselves as 
disabled than the Dutch (Kapteyn, Smith, and van Soest 2007). 
  Even if incidence data were available, analysts would have to disentangle the role of 
personal behavioral and social histories from that of health system performance. And these are 
not always readily distinguishable. Are the historically high rates of smoking in the US 
attributable to the failure of the US public health system to stem the smoking tide? The fact that 
Canada had for many years the second highest consumption of cigarettes per adult (Forey et al. 
2002) makes it appear that geographic factors, perhaps related to conditions for growing or 
importing tobacco, had more to do with consumption patterns than did health systems. And 
public health authorities were not passive in the US. The US Surgeon General’s (1964) report on 
the health hazards of cigarette smoking was the first major indictment of the habit by a 
government authority and it was quickly followed up with a massive anti-smoking media 
campaign (Cutler and Glaeser 2006). The US had the largest reduction in manufactured 
cigarettes consumed per adult of any country between 1970 and 2000 (Forey et al. 2002). Some 
of that decline was likely attributable to public health efforts (Cutler and Glaeser 2006).  
  However it is achieved, the high prevalence of disease in the US adds considerably to 
health expenditure. Thorpe et al. (2007b) combine comparative prevalence data on 10 conditions   11
in HRS (in the US) and SHARE (in Europe) with Agency for Healthcare Research and Quality 
data on expenditure per medical condition for the population aged 50+. Their 95% confidence 
intervals on the per capita cost of higher disease prevalence in the US are $1,195 to $1,750  per 
year, or 12.7 to 18.7% of total personal health care spending among those aged 50+. 
Inefficiencies in the health care system are not solely responsible for high per capita health 
expenditures in the US; the high prevalence of major diseases is also substantially implicated  
(see also Michaud et al. 2009).  
 
    Case  Study  I.  Prostate  Cancer 
  Accounting for 31,000 deaths in 2000, prostate cancer was, after lung cancer, the second 
leading cause of cancer deaths among US men that year (US National Center for Health 
Statistics 2002). Unlike most chronic diseases, it is not associated with cigarette smoking 
(Lumey et al. 1997). A link with exercise has been suggested in several studies but a review 
article found that “conclusions were quite variable… odds ratios [of developing prostate cancer] 
for men engaged in high levels of activity ranged from 0.2 to over 2.0” (Torti and Matheson 
2004). Dietary risk factors are suspected but not well established. The risk of prostate cancer is 
somewhat higher for men with a high body mass index, but the risk is less than for other cancers 
(Crawford 2003). Genetic factors, some of them associated with race, appear to be important in 
the risk of developing prostate cancer (Li et al. 2007). Its relatively flat landscape of behavioral 
risk factors, together with its medical preventability, make mortality from prostate cancer a purer 
indicator of health system performance than mortality from many other chronic diseases of 
adulthood.   
 
A.  Prostate Cancer Screening 
  The Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) test are the 
primary screening tools for prostate cancer. As a screening test, DRE is of limited value because 
it cannot investigate the entire prostate gland (Ilic et al. 2006). It is more difficult to detect cancer 
with DRE than with the PSA test (Harris and Lohr 2002). The PSA test has the added benefits of 
being easy to perform, relatively inexpensive, and reproducible (Constantinou 2006). 
  The PSA blood test for the presence of prostate cancer was approved by the Food and 
Drug Administration in 1986 (Shampo 2002). The test enables the detection of high and/or   12
rapidly increasing levels of an antigen that often signals the presence of prostate cancer. High 
levels of the antigen can also be produced by other conditions; confirmation of cancer is made by 
transrectal ultrasound-guided biopsy (TRUS). 
  The PSA test is somewhat controversial. One reason is that, like many other medical 
screens, the PSA test can produce a false positive – a report of potential cancer when it is not 
present. According to a summary of studies of the sensitivity and specificity of PSA testing, an 
average of 75% of those with PSA readings above 4.0 ug/l have prostate cancer and 71% of men 
with prostate cancer have a PSA reading above 4.0 ug/l (Bunting 2002). However, the main 
reservation about the use of the PSA test is that treatment for prostate cancer can produce 
impotence and/or incontinence. Because of these side effects, several organizations have 
recommended against PSA testing for men over 75 (U.S. Preventive Services Task Force 2008). 
On the other hand, the American Cancer Society and the American Urological Association 
recommend that the PSA test should be offered annually to men over 50 with at least a 10-year 
life expectancy.  
  By reputation the US has been the world leader in PSA testing, especially in the early 
years after the test was developed (Hsing, Tsao, and Devesa 2000; Levi et al. 2000; Vercelli et 
al. 200; De Koning et al. 2002; Bouchardy et al. 2008). Table 2 compiles the latest data that we 
were able to locate on the frequency of PSA testing in various countries or regions. The age 
ranges used and the survey dates are not identical from country to country, preventing exact 
comparisons. The United States has the highest recorded percentage ever tested at older ages 
(prevalence) as well as the highest percentage tested in a recent period (incidence).
6  
  Evidence about the efficacy of PSA testing from randomized controlled trials has been 
mixed. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial began in 
1993 and involved 76,693 US men aged 55-74. After 7 to 10 years of follow up, the death rate 
from prostate cancer did not differ significantly between the study and control group. As noted 
by the authors, one possible explanation of the negative result is that PSA testing is already so 
frequent in the US (see Table 2) that high levels of screening were already present among the 
control group. Furthermore, many cancers had already been identified in both treatment and 
control groups (Andriole et al. 2009). Results of the study are most reasonably interpreted as 
                                                 
6 Of the two sources of US data presented in Table 2, the BRFSS data are less reliable because they are based on a 
telephone survey with a low response rate.   13
addressing the question of whether mortality advantages would pertain to extending PSA testing 
in a population in which half of men are already being tested every two years.  
  The second trial, the European Randomized Study of Screening for Prostate Cancer, was 
more than twice as large and was conducted in a region where prostate cancer screening is much 
less common. The trial began in the early 1990’s in 7 European countries and included a total of 
162,243 men between the ages of 55 and 69. The study found that offering PSA screening to the 
treatment group reduced the death rate from prostate cancer by 20% (rate ratio of 0.73, 95% CI, 
0.56 to 0.90). The absolute reduction was 0.71 prostate-cancer deaths per 1,000 men. The median 
and average follow up times were 9 and 8.8 years, respectively; death rates in the two study 
groups began diverging after 7 to 8 years and continued to diverge subsequently (Schröder et al. 
2009).   
  The Goteborg, Sweden component of the European trial followed 20,000 randomly 
selected men aged 50–66 for 10 years. Half were invited for biennial PSA testing, with 10,000 
men serving as passive controls for whom diagnosis of metastatic prostate cancer was monitored 
by using the Swedish Cancer Registry. The risk of being diagnosed with metastatic, i.e., 
advanced, prostate cancer was reduced by 48.9% in the PSA treatment group relative to controls 
(p < .01) (Aus et al. 2007).    
  According to SEER, after the PSA test was introduced in the late 1980s, the recorded 
incidence of prostate cancer in the US rose from 119/100,000 in 1986 to a peak of 237/100,000 
in 1992 (SEER 2008).
7 The proportion of tumors that are metastatic was 25% of newly-
diagnosed tumors in 1980 and only 4% in 2002 (Etzioni et al. 2008). Consistent with more 
extensive screening, the United States identifies prostate cancer at an earlier stage, on average, 
than Sweden (Stattin et al. 2005), Japan (Ogawa et al. 2008), or the United Kingdom (Collin et 
al. 2008). Stage at diagnosis is particularly important in prognosis – if detected at an early stage, 
prostate cancer can be treated by radical prostatectomy or radiotherapy.  
 
B. Prostate Cancer Treatment 
Once prostate cancer is detected, a variety of treatments can be employed, including  
radical prostatectomy, radiation by beam (external beam radiotherapy) or implanted seeds  
(brachytherapy), or hormone therapy. “Watchful waiting” is also an option. Since 1991, radical  
                                                 
7 The data are for males and refer to the age-adjusted rates for all ages.   14
prostatectomy has been the most common treatment for localized prostate cancer in the US. It 
serves as the initial treatment for over a third of newly-diagnosed patients (Harris and Lohr 
2002). Observational studies have described apparent survival advantages from radical 
prostatectomy and radiation therapy (e.g., Wong et al. 2006;  Trock et al. 2008) but not always 
from hormone therapy alone (Lu-Yao et al. 2008). The questions of possible selection bias that 
are always present in observational studies add uncertainty to these results.  
  Uncertainty has been reduced by several recent reports of randomized clinical trials. A 
key study of Scandinavian men examined survival after diagnosis of prostate cancer. Men were 
randomly assigned to radical prostatectomy or to watchful waiting (Bill-Axelson et al. 2005). 
Some of those assigned to prostatectomy did not have the operation, and some of those assigned 
to watchful waiting pursued radiation or hormonal therapy. Nevertheless, after a median follow-
up period of 8.2 years, the group assigned to prostatectomy had cumulative proportions dead 
from prostate cancer that were lower by 44%, rates of disease progression that were lower by 
67%, and rates of distant metastasis that were lower by 40%. All comparisons were statistically 
significant (Ibid.).  
A randomized trial of variation in radiation dosage reported a highly significant 
beneficial effect on survival of heavier doses (Pollack et al. 2002). Another randomized trial of 
adjuvant radiotherapy enrolled 425 men with pathologically advanced prostate cancer who had 
undergone radical prostatectomy between 1988 and 1997. Adjuvant radiotherapy significantly 
reduced the risk of PSA relapse and disease recurrence, although improvements in survival were 
not statistically significant (Thompson et al. 2006).   
Several randomized clinical trials evaluate the use of hormone therapy as an adjunct to 
surgery or radiation in high risk patients; the value of hormone therapy used alone or as primary 
therapy has only been assessed by observational studies. A population-based cohort study found 
that primary androgen deprivation therapy does not improve survival in elderly men compared 
with conservative management (no surgery, radiation, or hormone therapy) (Lu-Yao et al. 2008). 
However, three phase III randomized trials have shown that a combination of radiotherapy and 
androgen suppression improve survival relative to radiotherapy alone (Bolla et al. 2002, Hanks et 
al. 2003, and Pilepich et al. 2005).  
 Population-based information about the frequency of various treatments of prostate 
cancer is much skimpier than information about the use of the PSA test. Among US men aged   15
65-80 in SEER who were diagnosed with low grade tumors between 1991 and 1999, 25.5% 
received no treatment within six months of diagnosis, 9.6% received hormone therapy, and the 
remaining 64.8% received either radiation or prostatectomy (Wong et al. 2006).  
Scandinavian countries rarely use radical therapies – radical prostatectomy or radiation – 
and rely primarily on watchful waiting or hormone therapy for palliation (Fleshner, Rakovitch, 
and Klotz 2000; Sandblom et al. 2000). For example, the fraction of patients treated with 
curative intent in Norway was only 3% in 1985-1989 and rose to 6% in 1990-1994.  In 1990-
1994, radical prostatectomy was used to treat only 3.0 and 3.3% of all patients diagnosed with 
prostate cancer in Norway and Sweden, respectively (Kvåle et al. 2007). Low levels of surgery 
and radiation therapy are also reported in Japan (Ogawa et al. 2008).   
Differences in treatment approach also exist between the US and the UK, with US 
approaches generally being more aggressive, particularly in the use of surgery (Collin et al. 
2008). A survey of American and Canadian urologists indicated that American urologists tended 
to have a more aggressive approach to case identification and surgical intervention. They were 
also more likely to perform radical prostatectomy on patients over the age of 70 (Fleshner, 
Rakovitch, and Klotz 2000).   
 
C. Prostate Cancer Survival 
The combination of earlier detection and aggressive treatment in the US has produced 
greatly improved survival chances for men diagnosed with prostate cancer. 5-year relative 
survival rates in the US increased from 71% to 83% between 1984-86 and 1987-89, whereas 
European rates improved from 55% to 59% during the same period (Post et al. 1998). According 
to SEER (2008), the US 5-year relative survival rate had increased to 99.2% for those diagnosed  
in 2000.  
  Gatta et al. (2000) compared international survival rates for cancers diagnosed between 
1985 and 1989. All of the European countries considered had lower prostate cancer survival rates 
than the US. European patients had a 4.1 times greater risk of dying in the first year after 
diagnosis, suggesting that earlier diagnosis plays an important role in these survival differences 
(Ibid.).  The updated study whose results are presented in Table 1 found that 5-year survival rates 
for prostate cancer in 2000-02 were 99.3% in the US compared to 77.5% in Europe. 
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D. Prostate Cancer Mortality  
Population-level data on mortality have one distinct advantage over data on survival rates 
among those newly diagnosed: they are not subject to lead-time bias. If one country is 
diagnosing cancer sooner than another but early diagnosis does not alter the clinical course of the 
disease and delay or prevent death, then that country will enjoy no advantage in mortality as a 
result of its earlier diagnoses. When early diagnosis improves prognosis, population-level 
mortality is responsive to the timeliness of diagnosis. It is also responsive to the efficacy of 
treatments employed regardless of stage at diagnosis. Mortality data has a similar advantage 
relative to recorded incidence and prevalence data, both of which are subject to lead-time bias. 
In order to investigate whether the relatively aggressive use of PSA testing and therapy in 
the United States has produced an unusually rapid decline in mortality from prostate cancer, we 
have used World Health Organization data on deaths by cause and population by five-year age 
groups. We have chosen a group of 15 economically developed OECD countries for purposes of 
comparison: Australia, Austria, Canada, Finland, France, Germany, Greece, Italy, Japan, the 
Netherlands, Norway, Spain, Sweden, Switzerland, and United Kingdom. 
Figure 3 compares levels of age-standardized death rates per 100,000 (all ages combined) 
in the United States to the unweighted mean death rate in these 15 comparison countries.
8 With 
the exception of 1985, the US had higher deaths rates each year from 1980 to 1995. Beginning in 
1996, the US had lower rates and the US advantage grew every year thereafter. By 2003, the US 
had death rates that were 20.4% lower than the mean of the comparison countries. Mortality rates 
among men 60-79 were lower in 1997 than in any year since 1950 (Tarone, Chu, and Brawley 
2000). Baade, Coory, and Aitken (2004) note that changes in risk factors and in the accuracy of 
or procedures for recording cause-of-death information are unlikely to be responsible for the 
observed trends.  
Declines in prostate cancer mortality have been attributed to both PSA screening and 
improvements in treatment (Baade et al. 2004; Potosky, Feuer, and Levin 2001; Bouchardy et al. 
(2008), Kvåle et al. (2007), Collin et al. (2008).) An individual-level population model that used 
counterfactuals to simulate US mortality and incidence of advanced-stage prostate cancer 
concluded that two-thirds of the decline in mortality between 1990 and 1999, and 80% of the  
                                                 
8 These rates are taken from the International Agency for Research on Cancer (http://www-dep.iarc.fr/), which 
extracts the World Health Organization mortality data and standardizes the rates to the world population in 1960 
(Segi world standard).    17
decline in distant-stage incidence, was attributable to expanded PSA testing (Etzioni et al. 2008). 
  To test whether the faster mortality decline in the US was statistically significant, we use 
a negative binomial regression in a fixed-effects model applied to data for these 16 countries for 
the period 1982 to 2005. The dependent variable is the log of the number of deaths from prostate 
cancer in a particular age, country and year cell, with population size in a particular cell used as 
the exposure. Independent variables are a set of age group identifiers, a set of period identifiers, a 
dummy variable for the US, and a set of US/period interactions. Six 4-year-wide time periods are 
used, beginning with 1982-85 and ending with 2002-05. 1982-1985, the period before PSA 
testing was begun, is chosen as the reference period. Significance tests recognize the clustering 
of observations by country. Results are presented in Table 4.  
  The coefficient of the interactive variable for US observations during the period 2002-05 
is -0.274, which is significant at p < .001. Compared to expectations based upon country and 
year, the US had roughly 27% lower mortality in 2002-05 than it did in 1982-85. (The US/2002-
2005 variable is always significant at p < 0.001 regardless of reference period used). Likewise, 
the coefficient of the US/period interactive variable for the 1998-2001 period is -0.215 and is 
also significant at p < .001. So the US had significantly faster declines in mortality than did 
comparison countries between 1982-85 and both 1998-2001 and 2002-05.   
  Mortality trends from prostate cancer may be affected by “attribution bias”: people who 
have had prostate cancer detected may be more likely to have their death ascribed to it even 
though some other morbid process were actually responsible (Feuer et al. 1999). Such bias, 
combined with more aggressive screening, would produce a rise rather than a fall in prostate 
cancer mortality. This bias may account for the rise in prostate cancer mortality in the late 80s 
and early 90s (Figure 3), but it obviously would minimize rather than accentuate the actual 
decline that is observed between 1982-85 and 2002-05.  
  African Americans have prostate cancer death rates that are among the highest in the 
world (Crawford 2003). Perhaps the most prominent explanation of the racial disparity is that 
dark skin inhibits the absorption of Vitamin D, which is highly protective against prostate cancer 
(Li et al. 2007). A more tenuous connection to the health care system among African Americans 
is probably also a factor. Nevertheless, a sharp decline in prostate cancer mortality in the US is 
evident among both whites and African Americans. Both whites and blacks had rates that peaked 
in the early 1990s. Between 1992/3 and 2004/5, the death rate declined by 32.2% for African   18
Americans and by 36.3% for whites (Ibid.). The absolute decline in rates was much larger for 
African Americans. The 5-year survival rate for blacks increased from 68.4% for those 
diagnosed in 1986, the year when PSA testing was approved, to 97.0% for those diagnosed in 
2000. Among whites, the improvement was from 79.0% to 99.8% (SEER 2008).  
 
          Case Study II. Breast Cancer 
Breast cancer is the most common cause of cancer death among women in a majority of 
high income countries (Vainio and Bianchini 2002). In contrast to prostate cancer, there are 
important behavioral risk factors for breast cancer. These include childlessness or low parity, late 
age at first birth, obesity, and use of hormone replacement therapy (Das et al. 2005; Levi et al. 
2005). Thus, trends in mortality are more difficult to interpret as exclusively reflecting medical 
factors. But, like prostate cancer, breast cancer is highly amenable to medical intervention 
through screening and therapy.   
 
A.  Breast Cancer Screening 
Mammography, breast self-examination, clinical breast examination (CBE), and 
magnetic resonance imaging (MRI) are used to screen for breast cancer. No randomized trials of 
CBE alone have been completed, and case-control and ecological studies have provided only 
limited evidence for its efficacy in reducing mortality from breast cancer (Vainio and Bianchini 
2002). Breast self-examination is an appealing screening method because it is noninvasive, but it 
has weak ability to detect breast cancer (Elmore et al. 2005). Two randomized trials of breast 
self-examination have been conducted, and neither found evidence of mortality reduction. The 
International Agency for Research on Cancer (IARC) has concluded that there is inadequate 
evidence for the efficacy of CBE and breast self-examination in reducing breast cancer mortality 
(Vainio and Bianchini 2002). The US Preventive Services Task Force also found evidence from 
trials involving CBE and breast self-examination to be inconclusive (Humphrey et al. 2002). The 
third technique, MRI, is mainly employed in high risk patients and after conventional diagnostic 
procedures have already been conducted (Veronesi et al. 2005). Because of its high cost 
(approximately 10 times that of mammography) and its relatively low specificity, MRI is not a 
feasible tool for routine screening in the general population (Elmore et al. 2005).   
Thus, mammography is currently the most important diagnostic tool for breast cancer. It   19
 is the only screening test that has been shown to reduce mortality from breast cancer in  
randomized trials and population studies (Veronesi et al. 2005; Wells 1998). The International 
Agency for Research on Cancer (IARC) concluded that there is sufficient evidence from 
randomized trials that offering of mammography to a treatment group reduces breast cancer 
mortality in women aged 50-69, by an average of 25%. After adjusting for the effect of non-
acceptance of the screening invitation, this figure rises to 35% (Vainio and Bianchini 2002). The 
US Preventive Services Task Force reviewed eight randomized controlled trials of offering 
mammograms to treatment groups and concluded that, for studies of that were designated as of 
fair quality or better, the relative mortality risk for women aged 40-74 was 0.84 (95% CI, 0.77 to 
0.91) (Humphrey et al. 2002; see also Gøtzsche and Nielsen 2009). While some concerns have 
been raised concerning flaws in the trials’ design and execution, in-depth independent reviews 
have concluded that they do not negate the trials’ results (Quinn 2003).  
The National Cancer Institute and the American Cancer Society (ACS) issued the first 
formal guidelines for mammography in 1977, advocating screening for all women over the age 
of 50 (Wells 1998). Currently, all major US medical organizations recommend screening 
mammography for women over the age of 40 (Elmore et al. 2005; Ahern and Shen 2009). The 
US is the only country that strongly endorses screening mammography for women under age 50 
(Jatoi and Miller 2003); recent evidence has supported the efficacy of screening in the age group 
40-49 (Humphrey et al. 2002).  
Use of mammographic screening in the United States increased very rapidly; the 
percentage of women aged 50-64 who reported having a mammogram in the past 2 years 
increased from 31.7% in 1987 to 73.7% in 1998 (Breen et al. 2001). Screening programs 
generally began later in Europe than in the US (Møller et al. 2005). The start dates for organized 
screening programs in the countries under investigation range from 1986 to 1999 (Shapiro et al. 
1998; Jatoi and Miller 2003).  
Table 3 presents international data on the frequency of screening for breast cancer in 
recent years. In the early-to-mid 90s, the United States had the highest frequency of 
mammograms in the nine countries for which we are able to locate data. The OECD has 
collected more recent data which shows that, while the frequency of mammograms has increased 
in the US, it has grown faster in a number of other countries. Of the 19 countries shown in Table 
2, the United States ranks 6
th in the proportion of women in or around the age interval 50-69 who    20
had received mammograms in the previous two years.   
Consistent with the relatively high frequency of mammograms in the US, Sant et al. 
(2004) found that breast cancer is diagnosed at what is, on average, a later stage in Europe than 
in the US.  
 
B.  Breast Cancer Treatment 
In OECD countries, the large majority of cases of breast cancer are treated surgically. 
Surgery is often supplemented with some combination of radiotherapy, hormone therapy, and 
chemotherapy (i.e., adjuvant therapy). Descriptions of the Halsted mastectomy, which served as 
the treatment of choice for breast cancer for almost a century, were first published in 1894 
(Veronesi et al. 2002). It was later replaced by the modified radical mastectomy, which was 
popular in the 1980s (Cotlar et al. 2003). Neither the original Halsted radical mastectomy nor the 
modified radical mastectomy were introduced on the basis of evidence from randomized clinical 
trials; however, observational studies confirm an enormous survival advantage for surgery 
relative to no surgery (e.g., Sant et al. 2004). 
In most high income countries, breast conserving surgery (BCS, also known as 
lumpectomy) is currently the most common primary treatment for breast cancer (Veronesi et al. 
2005). Relative to total mastectomy, its advantages are reduced disfigurement and morbidity 
rather than mortality (Wood 1994). After 20 years of follow-up in a randomized trial, Fisher et 
al. (2002) report finding no differences in disease-free survival, distant-disease-free survival, or 
overall survival between women who underwent lumpectomy alone compared to those having a 
total mastectomy (see also Veronesi et al. 2002). In 1990, the National Institutes of Health 
Consensus Development Conference recommended breast conservation therapy for the majority 
of women with Stage I or II breast carcinoma.   
Radiation treatment of breast cancer was first used in 1896, but equipment and techniques 
have improved substantially, particularly since the 1960s (Ragaz et al. 1997). The Early Breast 
Cancer Trialists’ Collaborative Group conducted a meta-analysis of 36 trials of radiotherapy. 
They found that the local recurrence rate with radiotherapy and surgery was three times lower 
than with surgery alone, and that radiotherapy was associated with 6% reduction in the relative 
risk of death due to breast cancer (odds ratio, 0.94) (Early Breast Cancer Trialists’ Collaborative 
Group 1995). Ragaz et al. (1997) found that, after 15 years of follow-up, women assigned to   21
chemotherapy plus radiotherapy had a 33% reduction in the recurrence rate and a 29% reduction 
in mortality from breast cancer compared to women treated with chemotherapy alone.   
Adjuvant systemic multi-agent chemotherapy and tamoxifen have been estimated to  
reduce mortality (in terms of the relative reduction of the annual odds of death) by 27% and 
47%, respectively (Early Breast Cancer Trialists’ Collaborative Group 1998a, 1998b). These 
figures are derived from the meta-analyses of all randomized trials of any aspect of treatment for 
early breast cancer that began before 1990. There were 47 trials of adjuvant polychemotherapy  
involving 18,000 women (Early Breast Cancer Trialists’ Collaborative Group 1998a). Greater 
benefits were reported in women under the age of 50, who experienced with significant 
reductions in recurrence and mortality of 35% and 27%. For women between 50 and 69, these 
figures were 20% and 11% (Ibid.). 
Cole et al. first reported the clinical efficacy of tamoxifen for disseminated breast cancer 
in 1971.  The Early Breast Cancer Trialists’ Collaborative Group summarized the results of 55 
randomized controlled trials involving more than 37,000 women. Compared to a placebo, 
adjuvant tamoxifen resulted in annual reductions of 26% in recurrence and 14% in death. Among 
women treated for five years, these figures rose to 50% and 28%, respectively (Early Breast 
Cancer Trialists’ Collaborative Group 1998b; Osborne 1998) Tamoxifen produces significant 
benefits in women of all age groups (Jaiyesimi et al. 1995; Early Breast Cancer Trialists’ 
Collaborative Group 1998b). Following pharmacologic and clinical evaluations, the US Food 
and Drug Administration approved tamoxifen for the treatment of metastatic breast cancer in 
postmenopausal women in 1977. Tamoxifen was also approved as the initial endocrine therapy 
for disseminated breast cancer in premenopausal women.  
Information on international differences in breast cancer treatment is limited. A 
comparison of the Eurocare and SEER registry data found that 97% of women in SEER  were 
treated surgically compared to 90% in the Eurocare registries. Lymphadenectomy rates were 
slightly more extensive in the US, and more axillary lymph nodes were examined in the US 
(Sant et al. 2004). Hughes (2003) compared patterns of breast cancer care in Belgium, Canada 
(Manitoba and Ontario), France, Italy, Norway, Sweden, United Kingdom (England), and the 
United States. During the latest period investigated, 1990-93, at least 90% of women diagnosed 
with breast cancer received a mastectomy or breast-conserving surgery in all areas except 
Ontario, where the figure was 82%, and England (71%).  The use of radiotherapy with BCS has   22
also risen over time and varied considerably among countries. Among women receiving BCS in 
1995-97, Belgium, France, Canada and the UK had the highest proportions of women receiving 
radiation therapy. The US ranked below these countries and above Sweden and Italy (Ibid.)  
Adjuvant chemotherapy became standard treatment for breast cancer patients in the US in 
the late 1970s (Ragaz et al. 1997). Tamoxifen began to be widely used in the late 1970s and early 
1980s after the Nolvadex Adjuvant Trial Organization trials demonstrated its effectiveness 
(Mariotto et al. 2002). It has since become the most widely prescribed antineoplastic agent for 
treatment of breast cancer in the United States and Great Britain (Jaiyesimi et al. 1995). Between 
1975 and 2000, the percentage of breast cancer patients receiving chemotherapy in the US 
increased from essentially 0 to 80%, while tamoxifen use increased from 0 to 50% (Berry et al. 
2006). Starting in the mid-1980s, tamoxifen use in the UK also increased rapidly. By 1990, 50% 
of women with breast cancer over the age of 50 in the Thames region were receiving tamoxifen 
(Blanks et al. 2000). Unfortunately, we have not found comparable international data on the use 
of chemotherapy and tamoxifen. Variations in stage and type of tumor, age of patient, type of 
surgery, and other factors make it impossible to reliably compare the few national or regional 
data that exist. 
 
C.  Breast Cancer Survival  
Several studies have compared international survival rates from breast cancer. As 
noted above, the survival advantage of US breast cancer patients compared to their European 
counterparts is well documented. The US survival advantage is particularly sharp among older 
women (Hughes 2003). International differences in survival are challenging to interpret, but 
three studies using cancer registry data for European and American women cancer survival have 
attributed the survival differences from breast cancer to earlier diagnosis and more aggressive 
care in the US. These factors have also been introduced to explain better breast cancer survival 
rates in the US than in Canada (Ugnat et al. 2005).   
Gatta et al. (2002) found that European breast cancer patients diagnosed 1985-89 had 
significantly lower five-year relative survival rates than American patients (73% vs. 82%). None 
of the 17 European countries had higher five-year relative survival than the US. In the first year 
after diagnosis, the risk of death from breast cancer was much higher in European than American 
patients. Survival rates fell with increasing age at diagnosis in both the US and Europe, but the   23
fall was more marked in Europe. Gatta et al. suggest that the survival rate differences may be 
attributable to earlier diagnosis in the US.   
The most thorough study compared American and European women diagnosed with 
breast cancer between 1990 and 1992 (Sant et al. 2004). The five-year survival rate was higher in 
the US than in Europe (89% vs. 79%), and survival for each stage-at-diagnosis category was also 
higher in the US. Early-stage tumors were more frequent in the US (41% of cases) than in 
Europe (29%). Treatment was more aggressive in the US, where 97.1% of women underwent 
surgery compared to 90.2% in Europe. In the US, 50.7% of women had 15+ lymph nodes 
evaluated for metastasis, compared to 27.8% in Europe. The overall relative risk of death was 
37% higher among European women (95% confidence interval 25-50%). The excess risk was 
reduced to 20% by adjustment for surgical intervention, which was associated with a 90% 
reduction in mortality. Adjustment for stage at diagnosis reduced the relative risk to 12% and 
further adjustment for the number of lymph nodes evaluated to determine cancer progression 
reduced the excess risk of death among the European women to an insignificant 7%. Introducing 
information on the use of radiotherapy did not alter the relative risk of European women. Thus, 
the higher survival rate in the US appears to be a result both of earlier diagnosis and more 
aggressive treatment.  
The most recent study compared cancer survival differences between Europe and the US 
in 2000-2002 based on period rather than cohort survival data. As shown in Table 1, the five-
year survival rate for breast cancer was 79.0% in Europe, compared with 90.1% in the US. 
Verdecchia et al. (2007) hypothesize that these differences were most likely due to differences in 
timeliness of diagnosis.  
Trends in screening and in survival in the US are consistent with the idea that earlier 
screening improves survival. The increase in the percentage of American women aged 50-64 
with a mammogram in the previous two years from 32% in 1987 to 74% in 1998 was 
accompanied by an increase in five-year survival rates from 79% for those diagnosed in 1985 to 
91% for those diagnosed in 2000 (SEER 2008). 
 
D.  Breast Cancer Mortality 
  In many developed countries, breast cancer mortality rates began declining around 1990 
(Veronesi et al. 2005; Botha et al. 2003). It is unlikely that the declines in mortality were caused   24
by changes in the major risk factors for the disease. In fact, the risk factor profile of women in 
high income countries has, if anything, become less favorable over the past few decades as a 
result of rising obesity and delayed and reduced childbearing (Levi et al. 2005). Reductions after 
2002 in the use of hormone replacement therapy could work in the opposite direction but the risk 
is sufficiently small (Writing Group for the Women’s Health Initiative Investigators 2002; 
Chlebowski et al 2003), and lags sufficiently long, that the decline should not be reflected in a 
data series that ends in 2005. Chu et al. (1996) rule out changes in coding or ascertainment as 
contributors to the mortality decline in the US, noting that there had been no coding changes 
affecting breast cancer and that no systematic problems with ascertainment were identified after 
1989.   
  Studies of trends in breast cancer mortality have attributed the declines mainly to earlier  
detection – in particular, rising rates of mammographic screening – and improved treatment 
(Veronesi et al. 2005; Levi et al. 2005; Chu et al. 1996). A careful, detailed simulation for the US 
by Berry et al. (2006) concluded that “We can say with high probability that both screening and 
adjuvant therapy have contributed to the reductions in U.S. breast cancer mortality observed 
from 1975 (and especially from 1990) to 2000. Our best estimate is that about two-thirds of the 
reduction is due to therapy and one-third to screening” (Berry et al. 2006:36). Using less precise 
methods, Blanks et al. (2000) reached a similar conclusion about the decline in breast cancer 
mortality in England and Wales from 1990 to 1998. Evidence that states with greater use of 
mammography had greater mortality declines between 1992 and 1999 supports the link between 
screening and mortality (Das et al. 2005).   
  We hypothesize that the US has had a faster decline in breast cancer mortality than the  
comparison countries because it took better advantage of technological advances in screening 
and treatment. Mortality data alone do not permit us to distinguish between the effects of 
screening and treatment, but that distinction is not central to judging the effectiveness of a health 
care system.  
  Figure 4 shows the annual age-standardized death rate in the United States and the 
average for our 15 OECD countries since 1980. Clearly, the US has had a faster decline in breast 
cancer mortality than average among the comparison countries. Is the faster decline in the US 
statistically significant? To answer this question, we repeat the approach used for prostate 
cancer, using WHO data files on deaths by cause and population by five-year age groups. We   25
employ negative binomial regression on data at ages 50+ (in five-year wide age groups until 
85+). The dependent variable is the log of the number of deaths from breast cancer in a certain 
age group for a particular country and time period. Independent variables are a set of age group 
identifiers, a set of period identifiers, a dummy variable for the US, and a set of US/period 
interactions. We designate six 4-year-wide time periods, beginning with 1982-85 and ending 
with 2002-05, and choose 1982-85 as the reference period. Because of the rapid increase in the 
proportion of women receiving mammograms from less than a third in 1987 to 74% in 1998, a 
reference period in the early 1980s appears appropriate. Significance tests recognize the 
clustering of observations by country. Results are presented in Table 4.  
Using 1982-85 as the reference period, we find that the US/2002-05 interaction term is  
significant at .01. With a coefficient of -.126, the coefficient implies that mortality in the US has 
fallen 13% faster since 1982-85 than in other countries. US interactive coefficients for 1994-97 
and 1998-2001 are also negative and significant at 5%. The interactive variable, US/2002-2005, 
is always significant at p < 0.01 regardless of which date is selected as reference period (not 
shown). Thus, the US has experienced a significantly faster decline in breast cancer mortality 
than comparison countries. 
    
Summary  
  We have demonstrated that mortality reductions from prostate cancer and breast cancer 
have been exceptionally rapid in the United States relative to a set of peer countries. We have 
argued that these unusually rapid declines are attributable to wider screening and more 
aggressive treatment of these diseases in the US. It appears that the US medical care system has 
worked effectively to reduce mortality from these important causes of death. 
  This conclusion is consistent with other evidence that we have reviewed on the 
performance of the US health care system: screening for other cancers also appears unusually 
extensive; 5-year survival rates from all of the major cancers are very favorable; survival rates 
following heart attack and stroke are also favorable (although one-year survival rates following 
stroke are not above average); the proportion of people with elevated blood pressure or 
cholesterol levels who are receiving medication is well above European standards. 
  These performance indicators pertain primarily to what happens after a disease has 
developed. It is possible that the US health care system performs poorly in preventing disease in   26
the first place. Unfortunately, there are no satisfactory international comparisons of disease 
incidence. Individuals report a higher prevalence of cancer and cardiovascular disease in the 
United States than in Europe, and biomarkers confirm the higher prevalence of many disease 
syndromes in the US compared to England and Wales. Higher disease prevalence is prima facie 
evidence of higher disease incidence, although it could also be produced by better identification 
(e.g., through screening programs) or better survival. The history of exceptionally heavy 
smoking in the US, and the more recent massive increase in obesity, suggest that a high disease 
incidence in the US could not be laid entirely at the feet of the health care system.  
  Evidence that the major diseases are effectively diagnosed and treated in the US   
does not mean that there may not be great inefficiencies in the US health care system. A list of 
prominent charges include fragmentation, duplication, inaccessibility of records, the practice of 
defensive medicine, misalignment of physician and patient incentives, limitations of access for a 
large fraction of the population, and excessively fast adoption of unproven technologies (Garber 
and Skinner, 2008; Cebul et al. 2008; Commonwealth Fund 2008). Some of these inefficiencies 
have been identified by comparing performance across regions of the United States. Of course, 
the fact that certain regions do poorly relative to others does not imply that the US does poorly 
relative to other countries. And many of the documented inefficiencies of the US health care 
system add to its costs rather than harm patients.     
  Just as we are not addressing issues of efficiency on the production side, we are not 
treating patient welfare as the main outcome. Practices that produce greater longevity do not 
necessarily enhance well-being. This potential disparity is central to the controversy involving 
PSA testing, which uncovers many cancers that would never kill patients but whose treatment 
often produces adverse side effects.  
  The question that we have posed is much simpler: does a poor performance by the US 
health care system account for the low international ranking of longevity in the US? Our answer 
is, “no”.   27
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Table 1. Five-Year Relative Survival Rates for Cancer of Different Sites, US and European                
              Cancer Registries* 
 
  
  5-year survival rate (%) 
    
Site United  States  Europe 
    
Prostate 99.3  77.5 
Skin melanoma  92.3  86.1 
Breast 90.1  79.0 
Corpus uteri  82.3  78.0 
Colorectum 65.5  56.2 
Non-Hodgkin lymphoma  62.0  54.6 
Stomach 25.0  24.9 
Lung 15.7  10.9 
    
    
All malignancies (men)  66.3  47.3 
All malignancies (women)  62.9  55.8 
    
    
*Based on period survival data for 2000-02 
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Table 2. Indicators of Frequency of PSA Testing Among Males 
 
A. Percent of Men Ever Receiving a PSA Test 
 
Country  Percentage of Men Ever 
Receiving a PSA Test  Year Age  Group  Source
Australia  49% 2003 40+  1
Austria 54.6%  2006-2007  40+  2 
Canada  47.5%
6  2000-2001  50+  3 
France  36%  2005  40-74  4 




6  1994  55-74  6 
Switzerland  
(Vaud and Neuchâtel 
Cantons) 
10%  “Early 1990s”  65+  7 










B. Percent of Men Recently Receiving a PSA Test 
 
Country 
Percentage of Men 
Receiving a PSA Test in 
the Past x Years 
x Year  Age 
Group  Source
Australia  27% 2 1995/1996  50+  10
Austria 31.1%  1  2006-2007  40+  2 
Belgium 
(Limburg Province)  23%  1  1996-1998  40+  11 
Canada 26%  1  2000-2001  40+  12 
Italy  15.9%  1  2002  50+  5 
Netherlands 
(Rotterdam)  20.2%  3  1997-2000  55-74  13 
Norway 
(3 counties)  7%  1  1999  50-65  14 
Spain 
(Getafe City)  20.9% 2  1997-1999  55+  15 
Sweden  25.3%
2  1  2002  50+  16 
United Kingdom  7%  1  1999-2001  45-84  17 











1 This figure does not include men with a history of prostate cancer. 
2 According to Sennfalt, Carlsson, and Varenhorst (2006), 430,000 PSA tests were performed in Sweden in 2002.  
We assume that all were performed on men aged 50+. The UN Population Division’s estimates for Sweden’s male   37
population (aged 50+) for 2000 and 2005 were retrieved from the UN Statistics Division’s Common Database and 
interpolated to give a figure for 2002 of 1,699,442. 
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Table 3. Percentage of Women Receiving a Mammogram in Previous Two Years: 1994 and       
              2003
1 
 
Country  Earlier Year  Later Year 
              
  % 
Screened  Year  Age 
Group  Source % 
Screened  Year  Age 
Group  Source 
              
Australia  51.4  1996-7 50-69  1  55.6  2003-
2004  50-69  10 
Austria  23.1 
35.7  1995  40-79 
50-54  2        
Belgium  49.2  1997  50-69  3  54.0  2003  50-69  10 
Canada 50  1994  50+  4  70.6  2003  50-69  10 
Finland          87.7  2003  50-59  10 
France       72.8  2003  50-69  10 
Hungary          60.2  2003  45-65  10 
Iceland       62.0  2003  40-69  10 
Ireland          79.5  2003  50-64  10 
Italy       29.0  2000  55-69  11 
Japan          2.6  2003  50-69  10 
Luxembourg       62.4  2003  50-69  10 
Netherlands  53.2  1994  50-69  5  79.0  2003  50-75  11 
New 
Zealand       62.3  2003  50-64  10 
Norway          98.0  2003  50-69  10 
Portugal       60.1  2003  50-69  10 
Spain  28  1994  40-70  6         
Sweden       83.6  2004  50-74  10 
Switzerland
2  20  1992-3 50-64  7  27.0  2002  50-69  11 
United 
Kingdom
3  63.9 1995  50-64  8  74.7 2003  50-64  10 
United 
States  66.5  1994  50-64  9  76.0  2003  50-69  10 
1 For later years, when there are two observations for the same country we use survey rather than program data in 
order to maximize comparability with the US (this affected only Canada and the Netherlands). 
2 For 1992-93, the data for Switzerland is for the canton of Vaud only, and the screening interval is 1 year. 
3 For the UK, the recall period is 3 years.   
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Table 4. Coefficients of Negative Binomial Regression Predicting the Log of the Number of  
              Deaths from Prostate and Breast Cancer
 
 
    
Variable Coefficient   
(standard error) 
    
  Prostate Cancer Breast Cancer 
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Observation from US  0.125 
(0.080) 
0.108 
(0.082)   42
    
Observation from US in    



































    
* p < 0.05, 
** p < 0.01, 
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